Halozyme Therapeutics Other Non-Current Liabilities 2010-2024 | HALO

Halozyme Therapeutics other non-current liabilities for the quarter ending December 31, 2024 were $0.055B, a 45.17% increase year-over-year.

  • Halozyme Therapeutics other non-current liabilities for 2024 were $0.055B, a 45.17% increase from 2023.
  • Halozyme Therapeutics other non-current liabilities for 2023 were $0.038B, a 21.67% decline from 2022.
  • Halozyme Therapeutics other non-current liabilities for 2022 were $0.048B, a 8752.57% increase from 2021.

Halozyme Therapeutics Other Non-Current Liabilities 2010-2024 | HALO

  • Halozyme Therapeutics other non-current liabilities for 2024 were $0.055B, a 45.17% increase from 2023.
  • Halozyme Therapeutics other non-current liabilities for 2023 were $0.038B, a 21.67% decline from 2022.
  • Halozyme Therapeutics other non-current liabilities for 2022 were $0.048B, a 8752.57% increase from 2021.